Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996-02-01

Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity.

L F Gulli, K C Palmer, Y Q Chen, K B Reddy

Index: Cell Growth Differ. 7(2) , 173-8, (1996)

Full Text: HTML

Abstract

A431 cells overexpress epidermal growth factor receptors (EGF-Rs) and are inhibited by EGF. We show that treatment of A431 cells with 10 nM EGF induced a 15-fold increase in EGF-R autophosphorylation, leading to inhibition of cell proliferation and morphological features of apoptosis. However, at a lower concentration of EGF (0.01 nM), there is a 2-fold increase in EGF-R autophosphorylation and increased cell proliferation when compared to untreated cells. EGF treatment is associated with increased expression of c-myc and decreased expression of mutant p53 and p21/WAF protein. When A431 cells were simultaneously treated with 10 nM EGF and EGF-R antibody, there was a significant reduction in EGF-R autophosphorylation that was associated with increased cell proliferation. Based on these results, we postulate that overexpression of EGF-R could allow for selective growth advantage for tumor cells in the presence of normal or decreased ligand availability. However, excessive ligand binding would result in deregulated growth signaling, leading to growth inhibition and programmed cell death.


Related Compounds

Related Articles:

The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice.

1991-08-15

[Cancer Res. 51 , 4430, (1991)]

Intrapituitary regulatory system of mammotrophs in the mouse.

2002-04-01

[Arch. Physiol. Biochem. 110(1-2) , 34-41, (2002)]

Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.

1992-07-01

[Cancer Res. 52(13) , 3636-41, (1992)]

Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice.

1995-11-01

[Cell Growth Differ. 6(11) , 1447-55, (1995)]

Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.

1996-03-01

[Mol. Cell. Endocrinol. 117(1) , 53-8, (1996)]

More Articles...